Dr Vibeke Strand: The Current State of Immunology Biosimilars and the Promise of Future Savings
In light of 2 blockbuster originators, namely Humira (adalimumab) and Stelara (ustekinumab), losing market exclusivity in 2023, 3 doctors penned supplement in The American Journal of Managed Care®. On this episode, Vibeke Strand, MD, one of the co-authors, explored how health systems can take charge and boost biosimilar adoption.
It's no secret that the immunology space for biosimilars is growing and growing fast, with between 8 and 10 adalimumab biosimilars and at least 2 ustekinumab biosimilars expected to launch in the United States throughout 2023. In light of 2 of the most profitable originators, namely Humira (adalimumab) and Stelara (ustekinumab), losing market exclusivity around the same time, 3 doctors in the immunology space penned a 3-article supplement in The American Journal of Managed Care® entitled "Biosimilars for Immune-Mediated Inflammatory Diseases: 2022 Update."
The Center for Biosimilars®, the sister website of The American Journal of Managed Care®, is conducting a multimedia interview series with the authors to expand on some of the information presented in the supplement. On this episode of Not So Different, we spoke with Vibeke Strand, MD, one of the co-authors and an adjunct clinical professor in the Division of Immunology/Rheumatology at Stanford University School of Medicine. We discussed the article "Overview of Biosimilars for Immune-Mediated Inflammatory Diseases: Summary of Current Evidence" as well as how health systems can take charge and try to boost biosimilar adoption.
Show notes
To read all the articles within the supplement, click here.
To read the article references in this episode, click here.
